Market Cap
$349.3M
OCGN
Ocugen, Inc.
$1.02 ▲ +2.00%
Prev close $1.00Market cap$349.3M
ConsensusStrong Buy
12-mo target$12.17 (+1092.8%)
▲ Bullish
Analyst conviction 9/10
24 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on OCGN right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$199.3M
Inst. Activity
24 buys / 11 sells
Insider Activity
$25.8K buy / $589.1K sell
Insider Net $
-$563.3K
Social Sentiment
82° Bullish
SEC Reports
9
Press Releases
5
Price chart 30d -24.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: OCGN — 61.7% short (1.4M / 2.3M)
Short: 1,443,123 | Exempt: 225 | TRF Vol: 2,337,587 | Short Ratio: 61.7% | Off-exchange volume (dark
Sep 9, 2026 Insider
Musunuri Shankar sold 468,727 shares
Chief Executive Officer @ $1.12 ($525.0K)
Sep 9, 2026 Insider
Sep 1, 2026 Press Musunuri Shankar sold 57,264 shares
Chief Executive Officer @ $1.12 ($64.1K)
Ocugen dosed the first patient in the global Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA) and highlighted
Impact 7/10
Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 modifier gene therapy for retinitis pigme
8-K — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
27,002,933 shares ($41.3M)
Jun 30, 2026 Inst.
STATE STREET CORP — DOUBLED
21,469,307 shares ($32.8M)
Jun 15, 2026 Insider
Johnson-Greene Treerita Essalima bought 21,000 shares
Chief Financial Officer @ $1.23 ($25.8K)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 27, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% |
Price targets
Where 6 covering analysts think OCGN trades over the next 12 months.
$12.17 +1092.8% upside Strong Buy
Current$1.02 Low$8.00 Median$10.50 High$22.00 6 analysts
$8.00$22.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
82°
Bullish
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 2 bullish, 0 bearish, 5 mixed, 2 neutral · avg impact 4.9/10.Plus 5 press releases.
BULLISH8-K6/10
Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 modifier gene therapy
Jul 13, 2026
NEUTRAL8-K2/10
Ocugen filed an 8-K reporting results from its June 11, 2026 Annual Meeting and the formal appointme
Jun 11, 2026
BULLISHINST-CLUSTER4/10
A small institutional cluster has formed in OCGN shares for Q4 2025, with five funds (led by State S
Jun 11, 2026
MIXED8-K6/10
Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrange
May 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: OCGN — 61.7% short (1.4M / 2.3M)
Short: 1,443,123 | Exempt: 225 | TRF Vol: 2,337,587 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
other
Ocugen to Participate in Upcoming Scientific Conferences
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing ge
Sep 30, 2026
short_volume
Short Volume: OCGN — 77.2% short (2.7M / 3.5M)
Short: 2,705,015 | Exempt: 3,437 | TRF Vol: 3,503,086 | Short Ratio: 77.2% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: OCGN — 70.7% short (1.9M / 2.7M)
Short: 1,907,021 | Exempt: 151 | TRF Vol: 2,695,890 | Short Ratio: 70.7% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: OCGN — 57.9% short (2.7M / 4.7M)
Short: 2,712,447 | Exempt: 997 | TRF Vol: 4,681,690 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.05 | $-0.07–$-0.04 | 23.8% | +0.0% | — | $0.0B | 3 |
| Next Q | $-0.06 | $-0.07–$-0.04 | 0.0% | +5.3% | — | $0.0B | 3 |
| Current FY | $-0.24 | $-0.27–$-0.18 | -2.9% | +12.3% | 2↑ 4↓ | $0.0B | 3 |
| Next FY | $-0.25 | $-0.32–$-0.18 | -7.0% | +5.0% | 1↑ 3↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.053 | — |
| 7d ago | $-0.053 | — |
| 30d ago | $-0.053 | — |
| 60d ago | $-0.052 | -0.001 |
| 90d ago | $-0.053 | — |
Institutional ownership
Which big funds own OCGN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $199.3M total value (130,216,821 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 24 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 27,002,933 | $41.3M | 20.7% | DOUBLED +269.7% |
| STATE STREET CORP | 21,469,307 | $32.8M | 16.5% | DOUBLED +122.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 14,372,598 | $22.0M | 11.0% | — |
| MILLENNIUM MANAGEMENT LLC | 13,943,252 | $21.3M | 10.7% | DOUBLED +154.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 8,871,013 | $13.6M | 6.8% | DOUBLED +109.9% |
| RTW INVESTMENTS, LP | 6,666,666 | $10.2M | 5.1% | NEW |
| UBS Group AG | 5,177,508 | $7.9M | 4.0% | TRIM -28.9% |
| MARSHALL WACE, LLP | 3,410,257 | $5.2M | 2.6% | TRIM -57.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,329,446 | $5.1M | 2.6% | DOUBLED +255.8% |
| NORTHERN TRUST CORP | 2,747,562 | $4.2M | 2.1% | DOUBLED +285.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 7,304,979 | 27,002,933 | +269.7% | $41.3M |
| STATE STREET CORP | DOUBLED | 9,670,191 | 21,469,307 | +122.0% | $32.8M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 4,227,104 | 8,871,013 | +109.9% | $13.6M |
| UBS Group AG | TRIM | 7,280,320 | 5,177,508 | -28.9% | $7.9M |
| MARSHALL WACE, LLP | TRIM | 8,052,350 | 3,410,257 | -57.6% | $5.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 935,799 | 3,329,446 | +255.8% | $5.1M |
| NORTHERN TRUST CORP | DOUBLED | 713,736 | 2,747,562 | +285.0% | $4.2M |
| Qube Research & Technologies Ltd | TRIM | 3,773,066 | 2,203,407 | -41.6% | $3.4M |
| BANK OF AMERICA CORP /DE/ | ADD | 1,174,180 | 1,990,636 | +69.5% | $3.0M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 212,094 | 1,042,537 | +391.5% | $1.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 11 transactions. Net -$563.3K — $25.8K bought, $589.1K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Musunuri Shankar | Chief Executive Officer | SELL | 468,727 | $1.12 | $525.0K |
| Sep 9, 2026 | Musunuri Shankar | Chief Executive Officer | SELL | 57,264 | $1.12 | $64.1K |
| Jun 15, 2026 | Johnson-Greene Treerita Essalima | Chief Financial Officer | BUY | 21,000 | $1.23 | $25.8K |
| Jun 11, 2026 | Coleman Blaise | Director | AWARD | 170,100 | — | — |
| Jun 11, 2026 | Zhang Junge | Director | AWARD | 170,100 | — | — |
| Jun 11, 2026 | Castillo Kirsten | Director | AWARD | 170,100 | — | — |
| Jun 11, 2026 | Chandrasekhar Satishchandran | Director | AWARD | 170,100 | — | — |
| Jun 11, 2026 | Kompella Uday | Director | AWARD | 170,100 | — | — |
| Apr 1, 2026 | Zhang Junge | Director | EXERCISE | 15,000 | $0.5100 | $7.7K |
| Apr 1, 2026 | Zhang Junge | Director | EXERCISE | 112,205 | $0.4600 | $51.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for OCGN.
Shares short
106,062,298
Settlement Sep 15, 2026
Change vs prior
+7.9%
Semi-monthly cycle
Days to cover
10.4
At avg daily volume
Of shares outstanding
≈31.3%
Estimate — not % of float
All OCGN filing & press-release reports (14)
- PRESS-RELEASE reportSep 1, 2026
- 8-K reportJul 13, 2026
- 8-K reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 4, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportMar 24, 2026
- 8-K reportMar 4, 2026
- 8-K reportMar 4, 2026
- PRESS-RELEASE reportMar 4, 2026
- PRESS-RELEASE reportMar 2, 2026